|drug3162||Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation Wiki||1.00|
|drug3165||Standard therapy recommended by the Ministry of Health of the Russian Federation. Wiki||1.00|
|drug3164||Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation Wiki||1.00|
|D011665||Pulmonary Valve Insufficiency NIH||0.38|
|D012141||Respiratory Tract Infections NIH||0.17|
There is one clinical trial.
The purpose of the study is to evaluate an effectiveness of the drug Dalargin for the prevention and treatment of severe pulmonary complications symptoms associated with severe and critical coronavirus infection cases (SARS COVID19, expanded as Severe acute respiratory syndrome Cоrona Virus Disease 2019 ). Test drug that will be administered to patients are: - Dalargin, solution for inhalation administration, - Dalargin, solution for intravenous and intramuscular administration.
Description: Estimated by Polymerase chain reaction (PCR)Measure: The change of viral load in patients with SARS-COVID-19. Time: Upon patient inclusion in the study, after 96 hours and on the 10day;
Description: Assessed through the entire patient participation in the studyMeasure: The frequency of development of Acute Respiratory Distress Syndrome (ADRS) Time: up to 10 days
Description: The number of days a patient is hospitalizedMeasure: Duration of hospitalization Time: up to 10 days
Description: Early mortality from all causes will be estimatedMeasure: The frequency of early mortality Time: up to 30 days
Description: Late mortality from all causes will be estimatedMeasure: The frequency of late mortality Time: up to 90 days
Description: Clinical status at the time of completion of participation in the study will be estimated based upon the following criteria: Death; Hospitalization is extended, on invasive mechanical ventilation of the lungs with extracorporeal membrane oxygenation; Hospitalization extended, on non-invasive ventilation; Hospitalization is extended, needs additional oxygen; Hospitalization is extended, additional oxygen is not required; Discharged.Measure: Clinical status at the time of completion of participation in the study Time: an average of 10 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports